Drug for Autism and Dementia is under clinical development by Palisades Therapeutics and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Drug for Autism and Dementia’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Drug for Autism and Dementia overview
The drug candidate is under development for the treatment of autism and dementia.
For a complete picture of Drug for Autism and Dementia’s drug-specific PTSR and LoA scores, buy the report here.